Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes

Kim Huynh, BBiomedSc (Hons), PhD, Naomi Aoki, MSc, BSc, Kihyun Kim, MD PhD, Wee Joo Chng, MD PhD, Gin Gin Gan, MBBS, MRCP, FRCP, Chang-Ki Min, MD PhD, Je-Jung Lee, MD PhD, Yeow Tee Goh, MBBS, Cameron Wellard, Zoe McQuilten, MBBS, PhD, Elizabeth M. Moore, PhD, Erica M. Wood, MBBS, FRACP, FRCPA, Andrew Spencer, MBBS, FRACP, FRCPA, DM

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136896

Published: 2020

Journal Articles

Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: An Open Label Phase II Australasian Leukaemia and Lymphoma Group (ALLG) MM 018/ Asian Myeloma Network (AMN) 002 Study

Hang Quach, MD, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP, Je-Jung Lee, MD PhD, Nichloas Murphy, MBBS, FRACP, FRCPA, Jae Hoon Lee, MD PhD, Kim Kihyun, MD, Jane Estell, FRACP, Noemi Horvath, MB ChB FRACP FRCPA, Richard Eek, FRACP., Bradley Augustson, MBBS FRACP FRCPA, Philip Campbell, MBBS, Rajeev Rajagopal, FRACP, Soo-Mee Bang, MDPhD, Jeffrey SY Huang, MD, PhD, Yoon Sung Soo, MD PhD, Belinda Butcher, BSci, MBiostat, PhD, Brian G.M. Durie, MD, Wee Joo Chng, MD PhD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-139174

Published: 2020

Journal Articles

Mapping the Functional Cofactors of Oncogenic EZH2 in Natural Killer/ T Cell Lymphoma (NKTL)

Boheng Li, Junli Yan, PhD, Tae-Hoon Chung, PhD, Pei Tsung Lee, Wee Joo Chng, MD PhD

Blood (2016) 128 (22): 1773.

https://doi.org/10.1182/blood.V128.22.1773.1773

Published: 2016

Journal Articles

Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

Shaji Kumar, MD, Meletios A Dimopoulos, Efstathios Kastritis, MD, Evangelos Terpos, Hareth Nahi, Hartmut Goldschmidt, MD, Jens Hillengass, MD, Xavier Leleu, Meral Beksac, MD, Melissa Alsina, MD, Albert Oriol, MD, Michele Cavo, MD, Enrique M. Ocio, MD PhD, Maria Victoria Mateos, Elizabeth K. O'Donnell, MD, Ravi Vij, MD MBA, Henk M. Lokhorst, MD PhD, Niels W.C.J. van de Donk, MD PhD, Chang-Ki Min, Tomer Mark, MD MSc, Ingemar Turesson, MD, PhD, Markus Hansson, MD, Heinz Ludwig, Sundar Jagannath, MD, Michel Delforge, MD PhD, Charalampia Kyriakou, MD PhD, Parameswaran Hari, MBBS, MD MRCP, Ulf-Henrik Mellqvist, MD PhD, Saad Z Usmani, MD FACP, Dominik Dytfeld, MD PhD, Ashraf Z Badros, MD, Philippe Moreau, Kihyun Kim, MD PhD, Paula Rodriguez Otero, MD, Jae Hoon Lee, MD, Chaim Shustik, MD, Daniel Waller, PhD, Wee Joo Chng, MD PhD, Shuji Ozaki, MD PhD, Je-Jung Lee, Javier de la Rubia, Hyeon Seok Eom, MD PhD, Laura Rosinol, MD PhD, Juan José Lahuerta, MD PhD, Anna Sureda, MD PhD, Jin Seok Kim, MD PhD, Brian G.M. Durie, MD

Blood (2016) 128 (22): 4414.

https://doi.org/10.1182/blood.V128.22.4414.4414

Published: 2016

Journal Articles

Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study

Blood (2015) 126 (23): 4201.

https://doi.org/10.1182/blood.V126.23.4201.4201

Published: 2015

Journal Articles

Functional Analysis of the CML Blast Crisis Transcriptome and Epigenome Using Crispr-CAS9 and Pharmacologic Approaches

Blood (2015) 126 (23): 2764.

https://doi.org/10.1182/blood.V126.23.2764.2764

Published: 2015

Journal Articles

The Genomic and Epigenomic Landscapes of Blast Crisis Transformation in Chronic Myeloid Leukemia

Blood (2015) 126 (23): 3737.

https://doi.org/10.1182/blood.V126.23.3737.3737

Published: 2015

Journal Articles

Marcks Marks Resistance to Proteasome Inhibitors: Exocytosis of Polyubiquitinated Proteins in Bortezomib-Resistant Leukemia Cells

Niels Franke, MD, Gertjan J.L. Kaspers, MD PhD, Yehuda G Assaraf, PhD, Johan Van Meerloo, MSc, Denise Niewerth, PhD, Terzah M. Horton, MD PhD, Wee Joo Chng, MD PhD, Chonglei Bi, B.S, Rene X. Menezes, PhD, Renée J. Musters, PhD, Pino J. Poddighe, PhD, Floortje Kessler, Serge Smeets, PhD, Bauke Ylstra, PhD, Sonja Zweegman, MD PhD, Gerrit Jansen, PhD, Jacqueline Cloos, PhD

Blood (2015) 126 (23): 3712.

https://doi.org/10.1182/blood.V126.23.3712.3712

Published: 2015

Journal Articles

PRIMA-1 (p53 Reactivation and Induction of Massive Apoptosis) Mediates Anti-Myeloma Effect through the ER Stress Pathway

Phaik Ju Teoh, Chonglei Bi, Sinto Sebastian, PhD, Rafael Fonseca, MD, Wee Joo Chng, MD PhD

Blood (2014) 124 (21): 2093.

https://doi.org/10.1182/blood.V124.21.2093.2093

Published: 2014

Journal Articles

MMSET Regulates IRF4, a Transcription Factor Critical for the Survival of T(4;14) Myeloma Myeloma Cells, and Its Silence Potentiates the Effect of Antimyeloma Agents

Zhigang Xie, PhD, Chonglei Bi, B.S, Jing Yuan Chooi, B.S, Zit Liang Chan, B.S, Nurulhuda Mustafa, PhD, Wee Joo Chng, MD PhD

Blood (2014) 124 (21): 171.

https://doi.org/10.1182/blood.V124.21.171.171

Published: 2014

Journal Articles

cIg-FISH On Patients with Multiple Myeloma – A Modified and Simple Technique Easily Incorporated Into Routine Clinical Service

Leena Gole, PhD, Adeline Lin, BSc, Constance Chua, MSc, Sok Peng Chua, BSc, Hui Bao Ma, BA, Wee Joo Chng, MD, PhD

Blood (2012) 120 (21): 4792.

https://doi.org/10.1182/blood.V120.21.4792.4792

Published: 2012

Journal Articles

Phase 1/2 Trial of a Novel CDK Inhibitor Dinaciclib (SCH727965) in Patients with Relapsed Multiple Myeloma Demonstrates Encouraging Single Agent Activity

Shaji K. Kumar, MD, Betsy R. LaPlant, Wee Joo Chng, MD, PhD, Jeffrey A. Zonder, MD, Natalie Callander, MD, Vivek Roy, M.D., Briant Furth, Charles Erlichman, MD, Keith Stewart, MBA, MB, CHB

Blood (2012) 120 (21): 76.

https://doi.org/10.1182/blood.V120.21.76.76

Published: 2012

Journal Articles

Clinical Profile of Multiple Myeloma in Asia - an Asian Myeloma Network (AMN) Study

Blood (2012) 120 (21): 5035.

https://doi.org/10.1182/blood.V120.21.5035.5035

Published: 2012

Journal Articles

ALK-Negative Anaplastic Large Cell Lymphomas with 6p25.3 Translocations Show a Histone-Modifying Gene Expression Signature

Andrew L. Feldman, MD, Gaofeng Huang, Julie C Porcher, Sertac Kip, MD, PhD, Stephen M Ansell, MD, PhD, Ahmet Dogan, Wee-Joo Chng, MD

Blood (2011) 118 (21): 88.

https://doi.org/10.1182/blood.V118.21.88.88

Published: 2011

Journal Articles

MYC Activation Is a Common Transformation Event in Myeloma and Associated with Poor Prognosis.

Wee-Joo Chng, MD, Gaofeng Huang, Siok-Bian Ng, Marta Chesi, PhD, Leif Bergsagel, Rafael Fonseca

Blood (2009) 114 (22): 834.

https://doi.org/10.1182/blood.V114.22.834.834

Published: 2009

Journal Articles

Loss of p53 Is a Marker of Progression in Plasma Cell Neoplasias and Is a Negative Prognostic Factor in Relapsed Disease.

Soledad Molnar, MD, Victor J Jimenez Zepeda, Scott Van Wier, Esteban Braggio, Jonathan Keats, Michael Kuehl, Tammy Price-Troska, Greg Ahmann, Rachel Rempel, Kim Henderson, MD, S. Vincent Rajkumar, MD, Philip. R Greipp, MD, Daniel Auclair, John Carpten, Angela Baker, Keith Stewart, MD, P. Leif Bergsagel, MD, Wee Joo Chng, MD, Rafael Fonseca, MD

Blood (2008) 112 (11): 1663.

https://doi.org/10.1182/blood.V112.11.1663.1663

Published: 2008

Journal Articles

Identification of Core Gene Signature Associated with Synergism Between ABT-869, a FLT3 Inhibitor and SAHA, a HDAC Inhibitor in AML with FLT3-ITD Mutation.

Jianbiao Zhou, MD, MS, Chonglei Bi, Bsc, Shaw-Cheng Liu, Wee-Joo Chng, MD, Kian-Ghee Tay, Bsc, Hanry Yu, Ph.D., Keith Glaser, Ph.D., Daniel Albert, PhD, BSc, Steven K Davidsen, Ph.D., Chien-Shing Chen, MD, PhD

Blood (2008) 112 (11): 1618.

https://doi.org/10.1182/blood.V112.11.1618.1618

Published: 2008

Journal Articles

RB1 Haploinsufficiency Confers a Proliferation Advantage in Myeloma Cell Lines.

Travis J. Henry, PhD, Wee Joo Chng, MD, John Carpten, PhD, P. Leif Bergsagel, MD, Rafael Fonseca, MD

Blood (2007) 110 (11): 2489.

https://doi.org/10.1182/blood.V110.11.2489.2489

Published: 2007

Journal Articles

Waldenström Macroglobulinaemia: The Impact of Cytogenetic Analysis.

Victor H. Jimenez-Zepeda, MD, Wee-Joo Chng, MD, PhD, Rafael Fonseca, MD

Blood (2007) 110 (11): 2490.

https://doi.org/10.1182/blood.V110.11.2490.2490

Published: 2007

Journal Articles

Dissecting Karyotypic Patterns in Non Hyperdiploid Multiple Myeloma: An Overview on the Karyotypic Evolution.

Victor H. Jimenez-Zepeda, MD, Wee-Joo Chng, MD, PhD, Rafael Fonseca, MD

Blood (2007) 110 (11): 2491.

https://doi.org/10.1182/blood.V110.11.2491.2491

Published: 2007

NARROW

The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes

Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: An Open Label Phase II Australasian Leukaemia and Lymphoma Group (ALLG) MM 018/ Asian Myeloma Network (AMN) 002 Study

Mapping the Functional Cofactors of Oncogenic EZH2 in Natural Killer/ T Cell Lymphoma (NKTL)

Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study

Functional Analysis of the CML Blast Crisis Transcriptome and Epigenome Using Crispr-CAS9 and Pharmacologic Approaches

The Genomic and Epigenomic Landscapes of Blast Crisis Transformation in Chronic Myeloid Leukemia

Marcks Marks Resistance to Proteasome Inhibitors: Exocytosis of Polyubiquitinated Proteins in Bortezomib-Resistant Leukemia Cells

PRIMA-1 (p53 Reactivation and Induction of Massive Apoptosis) Mediates Anti-Myeloma Effect through the ER Stress Pathway

MMSET Regulates IRF4, a Transcription Factor Critical for the Survival of T(4;14) Myeloma Myeloma Cells, and Its Silence Potentiates the Effect of Antimyeloma Agents

cIg-FISH On Patients with Multiple Myeloma – A Modified and Simple Technique Easily Incorporated Into Routine Clinical Service

Phase 1/2 Trial of a Novel CDK Inhibitor Dinaciclib (SCH727965) in Patients with Relapsed Multiple Myeloma Demonstrates Encouraging Single Agent Activity

Clinical Profile of Multiple Myeloma in Asia - an Asian Myeloma Network (AMN) Study

ALK-Negative Anaplastic Large Cell Lymphomas with 6p25.3 Translocations Show a Histone-Modifying Gene Expression Signature

MYC Activation Is a Common Transformation Event in Myeloma and Associated with Poor Prognosis.

Loss of p53 Is a Marker of Progression in Plasma Cell Neoplasias and Is a Negative Prognostic Factor in Relapsed Disease.

Identification of Core Gene Signature Associated with Synergism Between ABT-869, a FLT3 Inhibitor and SAHA, a HDAC Inhibitor in AML with FLT3-ITD Mutation.

RB1 Haploinsufficiency Confers a Proliferation Advantage in Myeloma Cell Lines.

Waldenström Macroglobulinaemia: The Impact of Cytogenetic Analysis.

Dissecting Karyotypic Patterns in Non Hyperdiploid Multiple Myeloma: An Overview on the Karyotypic Evolution.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only